

Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were \$22.4 billion. For more information, visit www.tevapharm.com.

Primary IR Contact

Investor Relations
Phone: (215) 591-3034
E-mail:
TevaIRus@tevapharm.com

Recent Headlines

- October 11, 2018
[Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions](#)

- October 10, 2018
[Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar](#)


- October 10, 2018
[Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® \(glatiramer acetate injection\) for the Treatment of Relapsing Forms of Multiple Sclerosis](#)

Upcoming Events

Date	Title
01-Nov-2018	Q3 2018 Teva Pharmaceutical Industries Ltd. Earnings Conference Call

Analyst Estimates / Ratings

Mean Recommendation: **3.0**



Unable to fulfill request.

SEC Filings

Filing Date	Form
10/09/18	4
09/20/18	4
09/20/18	4
09/20/18	4

Financial Reports

Date	
02/08/18	Fourth Quarter 2017 Earnings Press Release

Presentations

Date	
08/02/18	Teva Second Quarter Results 2018 Presentation

Corporate Officers

Kåre Schultz

President and CEO

Gianfranco Nazzi

Executive Vice President, Growth Markets Commercial

Iris Beck-Codner

Executive Vice President, Global Brand & Communications

Dr. Carlo de Notaristefani

Executive Vice President, Global Operations

Richard Daniell

Executive Vice President, European Commercial

Brendan O'Grady

Executive Vice President, North America Commercial

Sven Dethlefs

Executive Vice President, Global Marketing & Portfolio

Mark Sabag

Group Executive Vice President, Human Resources

Dr. Hafrun Fridriksdottir

Executive Vice President, Global R&D

David M. Stark

Group Executive Vice President, Chief Legal Officer

Michael (Mike) McClellan

Executive Vice President, Chief Financial Officer

Nir Baron

Executive Vice President, Chief Internal Auditor